Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-11-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartbrainradiationcontrolleduln
  Phrases that lowered it: clinicaldrugstrialsmaletreatments
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.4% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past trials: 175 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 40 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports with a death: 20.8% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 93.5% (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer NCT02648477 · started 2016 · scored riskier than 82% of active trials completed
• Ixabepilone + Carboplatin Metastatic Breast Cancer NCT01075100 · started 2010 · scored riskier than 98% of active trials completed
• Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer NCT01716715 · started 2012 · scored riskier than 26% of active trials completed
• Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer NCT01031446 · started 2009 · scored riskier than 98% of active trials completed
• Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer NCT01498588 · started 2011 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.